GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
2024年7月15日 - 10:05PM
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the
“Company”), a biotechnology company advancing an innovative
pipeline of Natural Killer T (NKT) cell modulators for the
treatment of inflammatory, fibrotic and autoimmune diseases, today
announced that it will participate in the Virtual Investor Lunch
Break Series on July 17, 2024 at 12:00 PM ET.
As part of the event, Marc Hertz, PhD, Chief
Executive Officer of GRI Bio, will provide a corporate overview and
business outlook. In addition to the moderated discussion,
investors and interested parties will have the opportunity to
submit questions live during the event. The Company will answer as
many questions as possible in the time allowed.
A live video webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (gribio.com). A webcast replay will be available
two hours following the live presentation and will be accessible
for 90 days.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical
company focused on fundamentally changing the way inflammatory,
fibrotic and autoimmune diseases are treated. GRI Bio’s therapies
are designed to target the activity of NKT cells, which are key
regulators earlier in the inflammatory cascade, to interrupt
disease progression and restore the immune system to homeostasis.
NKT cells are innate-like T cells that share properties of both NK
and T cells and are a functional link between the innate and
adaptive immune responses. Type 1 invariant (iNKT) cells play a
critical role in propagating the injury, inflammatory response, and
fibrosis observed in inflammatory and fibrotic indications. GRI
Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity
and is being developed as a novel oral therapeutic for the
treatment of idiopathic pulmonary fibrosis, a serious disease with
significant unmet need. The Company is also developing a pipeline
of novel type 2 NKT agonists for the treatment of systemic lupus
erythematosus. Additionally, with a library of over 500 proprietary
compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:JTC Team, LLCJenene
Thomas(833) 475-8247GRI@jtcir.com
GRI Bio (NASDAQ:GRI)
過去 株価チャート
から 7 2024 まで 8 2024
GRI Bio (NASDAQ:GRI)
過去 株価チャート
から 8 2023 まで 8 2024